ANTX vs. PBYI, CRBP, BMEA, VTYX, NBTX, VERU, TELO, TSVT, SGMT, and SAVA
Should you be buying (ANTX) stock or one of its competitors? The main competitors of (ANTX) include Puma Biotechnology (PBYI), Corbus Pharmaceuticals (CRBP), Biomea Fusion (BMEA), Ventyx Biosciences (VTYX), Nanobiotix (NBTX), Veru (VERU), Telomir Pharmaceuticals (TELO), 2seventy bio (TSVT), Sagimet Biosciences (SGMT), and Cassava Sciences (SAVA). These companies are all part of the "pharmaceutical preparations" industry.
(ANTX) vs.
Puma Biotechnology (NASDAQ:PBYI) and (ANTX) (NYSE:ANTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and risk.
Puma Biotechnology has higher revenue and earnings than (ANTX). (ANTX) is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
Puma Biotechnology received 456 more outperform votes than (ANTX) when rated by MarketBeat users. Likewise, 67.11% of users gave Puma Biotechnology an outperform vote while only 58.28% of users gave (ANTX) an outperform vote.
Puma Biotechnology currently has a consensus target price of $7.00, indicating a potential upside of 135.45%. (ANTX) has a consensus target price of $2.67, indicating a potential upside of 109.15%. Given Puma Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Puma Biotechnology is more favorable than (ANTX).
In the previous week, Puma Biotechnology had 1 more articles in the media than (ANTX). MarketBeat recorded 1 mentions for Puma Biotechnology and 0 mentions for (ANTX). (ANTX)'s average media sentiment score of 0.00 beat Puma Biotechnology's score of -0.50 indicating that (ANTX) is being referred to more favorably in the news media.
Puma Biotechnology has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, (ANTX) has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500.
Puma Biotechnology has a net margin of 9.56% compared to (ANTX)'s net margin of 0.00%. Puma Biotechnology's return on equity of 41.60% beat (ANTX)'s return on equity.
61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 90.5% of (ANTX) shares are held by institutional investors. 23.7% of Puma Biotechnology shares are held by company insiders. Comparatively, 20.8% of (ANTX) shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Puma Biotechnology beats (ANTX) on 13 of the 15 factors compared between the two stocks.
Get (ANTX) News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NYSE:ANTX) was last updated on 1/22/2025 by MarketBeat.com Staff
Free ANTX Stock Alerts